171 related articles for article (PubMed ID: 10917574)
1. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Cao TM; Negrin RS; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Taylor TL; Rizk NW; Wong RM; Blume KG; Hu WW
Biol Blood Marrow Transplant; 2000; 6(4):387-94. PubMed ID: 10917574
[TBL] [Abstract][Full Text] [Related]
2. Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation.
McGaughey DS; Nikcevich DA; Long GD; Vredenburgh JJ; Rizzieri D; Smith CA; Broadwater G; Loftis JS; McDonald C; Morris AK; Folz RF; Chao NF
Biol Blood Marrow Transplant; 2001; 7(5):274-8. PubMed ID: 11400949
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
Bearman SI; Overmoyer BA; Bolwell BJ; Taylor CW; Shpall EJ; Cagnoni PJ; Mechling BE; Ronk B; Barón AE; Purdy MH; Ross M; Jones RB
Bone Marrow Transplant; 1997 Dec; 20(11):931-7. PubMed ID: 9422471
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.
Cagnoni PJ; Nieto Y; Shpall EJ; Bearman SI; Barón AE; Ross M; Matthes S; Dunbar SE; Jones RB
J Clin Oncol; 1998 May; 16(5):1661-8. PubMed ID: 9586876
[TBL] [Abstract][Full Text] [Related]
5. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
Jones RB; Matthes S; Shpall EJ; Fisher JH; Stemmer SM; Dufton C; Stephens JK; Bearman SI
J Natl Cancer Inst; 1993 Apr; 85(8):640-7. PubMed ID: 8468721
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
[TBL] [Abstract][Full Text] [Related]
7. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment.
Chap L; Shpiner R; Levine M; Norton L; Lill M; Glaspy J
Bone Marrow Transplant; 1997 Dec; 20(12):1063-7. PubMed ID: 9466279
[TBL] [Abstract][Full Text] [Related]
9. Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Hu WW; Negrin RS; Stockerl-Goldstein K; Johnston LJ; Shizuru JA; Wong RM; Chao NJ; Long GD; Feiner RH; Blume KG
Biol Blood Marrow Transplant; 2000; 6(1):58-69. PubMed ID: 10708000
[TBL] [Abstract][Full Text] [Related]
10. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
Stuart MJ; Chao NS; Horning SJ; Wong RM; Negrin RS; Johnston LJ; Shizuru JA; Long GD; Blume KG; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2001; 7(10):552-60. PubMed ID: 11760087
[TBL] [Abstract][Full Text] [Related]
12. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.
Brockstein BE; Smiley C; Al-Sadir J; Williams SF
Bone Marrow Transplant; 2000 Apr; 25(8):885-94. PubMed ID: 10808211
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support.
Bhalla KS; Wilczynski SW; Abushamaa AM; Petros WP; McDonald CS; Loftis JS; Chao NJ; Vredenburgh JJ; Folz RJ
Am J Respir Crit Care Med; 2000 Jan; 161(1):17-25. PubMed ID: 10619792
[TBL] [Abstract][Full Text] [Related]
15. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer.
Nieto Y; Cagnoni PJ; Bearman SI; Shpall EJ; Matthes S; Jones RB
Biol Blood Marrow Transplant; 2000; 6(2A):198-203. PubMed ID: 10816028
[TBL] [Abstract][Full Text] [Related]
16. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
17. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
[TBL] [Abstract][Full Text] [Related]
18. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
19. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
[TBL] [Abstract][Full Text] [Related]
20. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]